Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORALLEEN: Ribociclib plus letrozole vs multi-agent chemotherapy as neoadjuvant treatment for Luminal B/HER2-negative breast cancer
2016-003098-17Phase 2Completed
- Sponsor
- SOLTI
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ribociclib and letrozole in Luminal B breast cancer (2 arms), sponsored by SOLTI. Primary endpoint: Residual cancer burden (RCB0/1) rate after neoadjuvant treatment. Started Feb 2017; status: completed.
02
Drugs
ribociclibletrozole
03
Conditions
Luminal B breast cancer
Beyond the preview
Go deeper on 2016-003098-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003098-17.